According to the announcement, the group is expected to incur a net loss of no more than 5 million Hong Kong dollars in the first half of 2024, while the net loss in the first half of 2023 was approximately 13.4 million Hong Kong dollars.

The announcement stated that the significant reduction in the expected loss is mainly due to the net exchange loss confirmed in the first half of 2024, which is approximately 1.2 million Hong Kong dollars, while the net exchange loss confirmed in the first half of 2023 was approximately 7 million Hong Kong dollars; and the impairment loss on trade and other receivables confirmed in the first half of 2024 is approximately 0.1 million Hong Kong dollars, while the impairment loss on trade and other receivables confirmed in the first half of 2023 was approximately 2.2 million Hong Kong dollars; and the decrease in marketing service fees and shipping expenses is consistent with the decrease in sales volume of the group's second-generation cephalosporin product (1.0 grams).